TY  - JOUR
AU  - Conde, Elisa
AU  - Earl, Julie
AU  - Crespo-Toro, Lorena
AU  - Blanco-Agudo, Carolina
AU  - Ramos-Muñoz, Edurne
AU  - Rodríguez-Serrano, E Macarena
AU  - Martínez Ávila, Jose Carlos
AU  - Salinas-Muñoz, Laura
AU  - Serrano-Huertas, Silvia
AU  - Ferreiro, Reyes
AU  - Rodriguez-Garrote, Mercedes
AU  - Sainz, Bruno
AU  - Massuti, Bartomeu
AU  - Alfonso, Pilar García
AU  - Benavides, Manuel
AU  - Aranda, Enrique
AU  - García-Bermejo, María Laura
AU  - Carrato, Alfredo
PY  - 2021
DO  - 10.3390/cancers13071710
SN  - 2072-6694
UR  - https://hdl.handle.net/10668/25897
T2  - Cancers
AB  - First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before treatment, we studied blood biomarkers and primary tumor molecules. We unveiled serum...
LA  - en
KW  - biomarkers
KW  - colorectal cancer
KW  - miRNAs
KW  - regorafenib
KW  - toxicity
KW  - treatment response
TI  - Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study.
TY  - research article
VL  - 13
ER  -